Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Dallo: You are a far more experienced stock market investor than I am. Do you have any insight into why the recently acquired small pharma called Amolyt which has one peptide drug in a Phase 3 trial, has been valued by AZN at $800 million up front plus a further $205 million dependent on achieving sales targets? At the same time IMM, with more peptide drugs on its P140 platform at |Phase 3 stage than Amolyt, is presently valued at £8 million and estimated by you to be worth £50 million. Why the enormous disparity in the value of these two small pharmas? I don't get it.
Dallo; I am following the same buying policy as you. I reckon any price below 2p is a real bargain.
Dallo:
Perhaps the news of acquisition by AZN of Amolyt, a small French pharma company which specialises in a peptide drug treatment of a rare disease may be filtering through to large pharmas also looking to strengthening their position in the treatment of autoimmune diseases. Bring on Immupharma. Doesn't it fit the bill?
And consider the price that AZN is prepared to spend to acquire Amolyt - $ 1.05 billion. Wow!
Alexander: As I have said before, you can't reason with Flash. You and I believe in the integrity of the IMM Board and are waiting and expecting announcements of new commercial partnerships which will finance IMM's research in the future.
Flash on the other hand has one objective: to depress the SP of IMM for as long as possible by dripping poisonous predictions of the SP falling below 1p. That is his only goal, at least on this bulletin board. But of facts he has none.
Pokerchips;
No one said that financing for a small pharma comes cheaply, so yes, and extra £2m in exchange for 100 million shares is a high price to pay. This is about survival with the goal being multi million bucks when the phase 3 trials are successful and deals are struck with other pharmas for the development for the drugs in the IMM pipeline.
That is why I still buy shares because the share price is below the 2p level which not so long ago was seen as unbelievably cheap. Hopefully we will soon see these ultra low prices recede into the past and the price will head back into double figures.
Dallo:
You are wasting your time trying to reason with dedicated naysayers like Lambo and Mystic Mike. I listened to Tim giving his Proactive interview today and found what he had to say persuasive.
I am somewhat glad that these naysayers exist - they help to depress the share price and allow me to continue to buy IMM shares at bargain basement prices - excellent news for me and my limited budget.
So carry on Mystic Mike and snivel away!
Wildbunch:
Wouldn't that be luvverly!
Thanks Dallo. Lisa's response to you is consistent with her response to me a week or two ago. Like you, I believe that she is honest in her belief that IMM has got a great future but it takes longer to achieve deals with prospective partners than investors (including herself?) had imagined.
Dallo:
Maybe she is working on a new RNS.
.....better.
ab: Thanks for your upbeat reflections. As good as a positive RNS.
Dallo
I'm sure that Lisa is only too well aware of the importance of issuing a RNS as soon as there is some news to report. But if there ain't any deal to report, there is not much she can do.
Only in the case of the Phase 3 Lupuzor trial is the company in more or less control of events and they must be surely trying to put a rocket under Simbec-Orion to get a move on with finalising patient recruitment and announcing a timetable for the Trial.
Wildtiger:
No, I have not sold and don't intend to throw in the towel at this stage.
Pig-headed? Stupid? Time will tell.
Adastra.
In your contribution of 24 January you commented " End February is time enough for things to fall into place."
And in your last contribution, on 7 February, you said "Having done lengthy background research I expect this to be a highly rewarding share."
Don't you think with the avalanche of share sells this morning that you were a little too optimistic about IMM having until end of February to pull off a significant collaboration on one of its pipeline drugs and/or announced a starting date for patient testing under the Ph3 Lupuzor trial? Such an announcement might have restored belief in the market enough to defeat the selling pressure.
What is the source of these clusters of sell orders?
"News tomorrow".
I wish!
Wildbunch, Adastra:
Along with yourselves and a few others, I am a long term investor because for more than a decade, I have been impressed by the scientific background of the CSNR, France's leading scientific research institution, which underpins P140 peptides, the platform for Lupuzor and the CIDP treatment. They are not a bunch of chancers and they still are backing IMM as can be seen by their predominance on the IMM Scientific Advisory Group.
Unfortunately, pharma is a complicated and lengthy business, and I am not equipped by training to judge the quality of these new drugs; I have to rely on the pedigree of those most closely involved with IMM development work, and in them I trust.
Like many long term shareholders, I have been slowly averaging down the average price of my IMM shares. Last week I reached the 2 milliion shares mark and have brought down my average share price well into single figures. I won't invest more because I am exposed more than enough to survive if the shares go bottom up, and with enough and more money if the Lupuzor, CIDP treatment, and others come good within the next 2- 3 years.
Adastra: "The reversal will take us all by surprise".
Surprise us! Bring it on! And the sooner the better!
Adastra:
Thanks for your email from which I take encouragement. I also bought today, on the dip, believing that these share prices will not be available for much longer. My buy is not recorded in today's transactions despite going through this morning.
Lambo222:
Ever-scornful. But go to the list of RNS notices of the past 2-3 years. There are reports on research that have been undertaken to satisfy the FDA such as the PK study which reported last year and plenty of activity to prove that much higher dosage levels of Lupuzor can be used safely than were employed on the first Ph3 trial. It's a slow business dealing with FDA and noone wants to end up with another failed trial, or one which causes serious side effects on patients further down the line.
I agree that it is frustrating to wait for news on the start of dosing of patients in this trial but there is nothing we can do to speed things up. We have to trust in the competence of IMM's and Avion's scientists, in collaboration with Simbec-Orion.
Lambo222:
Ever-scornful. But go to the list of RNS notices of the past 2-3 years. There are reports on research that have been undertaken to satisfy the FDA such as the PK study which reported last year and plenty of activity to prove that much higher dosage levels of Lupuzor can be used safely than were employed on the first Ph3 trial. It's a slow business dealing with FDA and noone wants to end up with another failed trial, or one which causes serious side effects on patients further down the line.
I agree that it is frustrating to wait for news on the start of dosing of patients in this trial but there is nothing we can do to speed things up. We have to trust in the competence of IMM's and Avion's scientists, in collaboration with Simbec-Orion.
Thanks, Adastra for your thoughts.
I always hoped that IMM fortunes would revive big time when Lupuzor and other formulations of peptide P140 would be successful. And then, that the glory days of 2018 when the SP reached 180p, would return. But if Alora realises before the rest of us that the present Ph 3 trial will be successful, it could gobble up IMM for pence, not pounds, and our dreams will evaporate.